Abstract
Immunotherapy is at the forefront of cancer treatment, and biomarkers are urgently needed to predict patient response to therapy. Recently, we discovered a 4-gene peripheral blood mRNA signature for prolonged survival in patients treated with tremelimumab. Peripheral blood mRNA is a readily accessible and under-utilized source of clinically relevant biomarkers.